沃森生物：子公司玉溪泽润双价HPV疫苗入围国家免疫规划疫苗集中采购项目

Core Viewpoint - Watson Bio's subsidiary, Yuxi Zerun Biotechnology, has been selected for the 2025 National Immunization Program's centralized procurement project for the bivalent human papillomavirus (HPV) vaccine, with a unit price of RMB 27.5 [1] Group 1 - The bivalent HPV vaccine is primarily used for the prevention of cervical cancer and other diseases, and it has already been launched in the domestic market and received pre-certification from the World Health Organization [1] - The inclusion in the procurement project is expected to expand the sales scale of the company's bivalent HPV vaccine and improve market coverage [1] - However, the short-term impact on the company's performance is limited, and there is uncertainty regarding the final results and actual effects [1]